Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 183 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Reaction to Drug Clear all
Completed Phase 3 Interventional Results available

Telotristat Etiprate for Carcinoid Syndrome Therapy

NCT02063659
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Telotristat etiprate, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Stanford, California • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

NCT00002586
View directory record Official record
Conditions
Drug Toxicity, Lung Cancer
Interventions
13-cis retinoic acid, Tocopherol
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2005
U.S. locations
4
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 1, 2026, 10:53 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

NCT06322238
View directory record Official record
Conditions
Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related
Interventions
PGx panel test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 1, 2026, 10:53 AM EDT
Not yet recruiting Not applicable Interventional

Maximizing Quality of Life After Cancer Through Rehabilitation

NCT07622407
View directory record Official record
Conditions
Head and Neck Cancer, Hearing Loss, Tinnitus, Dysphagia
Interventions
TIMELY REHAB
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

NCT00028964
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy
Dietary Supplement · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 1, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
Interventions
Rituxan, Cyclophosphamide, Etoposide, Etoposide phosphate, Carboplatin, Sodium thiosulfate, Neupogen, Neulasta, Cytarabine
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Months to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury

NCT06264752
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Level A, Level B, Passive Alert
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Altoona, Pennsylvania • Farrell, Pennsylvania • McKeesport, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 1, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

NCT01789047
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Interventions
Topiramate, Placebo, Amantadine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 1, 2026, 10:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Reduction of Adverse Drug Events and Readmissions

NCT02738047
View directory record Official record
Conditions
Pharmacogenomic Testing for Medication Management
Interventions
Not listed
Lead sponsor
ClinLogic LLC
Industry
Eligibility
25 Years and older
Enrollment
280,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 2Phase 3 Interventional

Improving Safety by Basic Computerizing Outpatient Prescribing

NCT01091038
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Basic Clinical Decision Support, Routine Care
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
228 participants
Timeline
2001 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 1, 2026, 10:53 AM EDT
Completed No phase listed Observational

Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin

NCT02423356
View directory record Official record
Conditions
Breast Neoplasms, Lymphoma, Sarcoma
Interventions
Echocardiogram
Procedure
Lead sponsor
Daniel Rushing
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 1, 2026, 10:53 AM EDT
Not listed No phase listed Observational

Diagnosing Adverse Drug Reactions Registry

NCT01970709
View directory record Official record
Conditions
Genetics of Drug Metabolism
Interventions
Not listed
Lead sponsor
Renaissance RX
Industry
Eligibility
18 Years and older
Enrollment
250,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 1, 2026, 10:53 AM EDT
Active, not recruiting Early Phase 1 Interventional

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

NCT04676399
View directory record Official record
Conditions
Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
Interventions
Hydrochlorothiazide 12.5mg, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 1, 2026, 10:53 AM EDT
Withdrawn No phase listed Observational

Implementation of a Pharmacist-led Pharmacogenomic Clinical Service

NCT04984538
View directory record Official record
Conditions
Adverse Drug Event, Drug Drug Interaction, Pharmacogenomics, Elderly
Interventions
Pharmacogenomic Testing
Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

NCT04262336
View directory record Official record
Conditions
Ototoxicity
Interventions
DB-020, Placebo
Drug
Lead sponsor
Decibel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Miami, Florida • Kansas City, Kansas • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration

NCT04397445
View directory record Official record
Conditions
Ranitidine Adverse Reaction, Pharmacokinetics, Food-drug Interaction
Interventions
Ranitidine, Placebo, Low nitrite/NDMA meals, High nitrite/NDMA meals
Drug · Other
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 1, 2026, 10:53 AM EDT
Not listed No phase listed Observational

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

NCT02081872
View directory record Official record
Conditions
Genetics of Drug Metabolism
Interventions
Not listed
Lead sponsor
Companion Dx Reference Lab, LLC
Industry
Eligibility
18 Years and older
Enrollment
279,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Scottsdale, Arizona • Augusta, Arkansas • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

NCT02428660
View directory record Official record
Conditions
Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, CYP2D6 Polymorphism
Interventions
Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM
Genetic · Other
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 1, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

NCT06192589
View directory record Official record
Conditions
Cannabidiol, Drug Induced Liver Injury, Drug Interaction
Interventions
Cannabidiol, Placebo, Citalopram, Morphine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 1, 2026, 10:53 AM EDT
Terminated Phase 4 Interventional Results available

Post-operative Pain Control After Pediatric Adenotonsillectomy

NCT02296840
View directory record Official record
Conditions
Recurrent Tonsillitis, Obstructive Sleep Apnea, Sleep Disordered Breathing, Adverse Reaction to Drug
Interventions
Ibuprofen, Hydrocodone-Acetaminophen
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 1, 2026, 10:53 AM EDT
Completed No phase listed Observational Results available

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

NCT03223428
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Xermelo
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 1, 2026, 10:53 AM EDT